Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- 14-Day Prescription Limit to Be Discussed toward Next Reform: MHLW Official
April 4, 2016
- Xarelto under Review for Thrombocytopenia Risk
April 4, 2016
- Clinical Research Bill Won’t Be Enacted in Current Diet Session: LDP Health Panel Chief
March 30, 2016
- MHLW OKs AZ’s Tagrisso, Novartis’s Zykadia for Lung Cancer
March 29, 2016
- PMDA to Establish Asian Regulatory Training Center on April 1
March 29, 2016
- Panel Finalizes “No Efficacy” Decision for Lysozyme, Pronase; MHLW Issues Notifications for Ethical, OTC Products
March 28, 2016
- Drug Makers, Distributors Won’t Set Interim Targets for Mandatory Barcode Labeling, but Keep Tabs on Progress
March 25, 2016
- MHLW Officially Sets Out Plan to Draw Up New Pharma Industry Vision
March 24, 2016
- Shiozaki Hints at Delay in MHLW Report on Vaccines and Blood Product Policies
March 24, 2016
- Ethical Hurdles for Placebo-Controlled Studies Could Be Cleared with Certain Designs: PMDA Panel
March 23, 2016
- MHLW Alerts on Risk of Respiratory Depression for Flunitrazepam Injectables, Orders Label Revision
March 23, 2016
- PMDA Chief Kondo Reappointed for 5th Term
March 23, 2016
- Drug Makers Should Ponder Their Role in Community-Based Integrated Care System: MHLW Official
March 22, 2016
- MHLW OKs Cymbalta’s New Pain Indication, Raises Caution on Its Use
March 22, 2016
- New Basic Guidelines for Hepatitis Measures to Push IFN-Free Therapies, Hep B Vaccines
March 18, 2016
- MHLW Official Asks Industry to Discuss Candidates for Essential Medicines
March 18, 2016
- Kamoya Prods Regulatory Science Society to Compile Essential Drug List
March 17, 2016
- Whether to Draw Line between 15 Billion and 100 Billion Yen Sales Thresholds for Re-Pricing Will Hold Key: Kamoya, Nakai
March 17, 2016
- Coefficient for New Generic Pricing “Will Decline Further” if Business Practices Are Not Changed: JGA Official
March 17, 2016
- Opdivo Gets Orphan Status for Hodgkin’s Lymphoma
March 17, 2016
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…